About Scilabs

A multidimensional firm committed to rethinking the standard approach to traditional pharmaceutical applications.

Read More

Research & Development

With patent pending technology, our team of experts is leading the change in pharmaceutical research and development.

Read More


AstraZeneca has announced the results of the Phase IV ATLANTIC study, which indicates that the profile of BRILINTA/BRILIQUE™ (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients. [...]
Tue, Sep 02, 2014 9:00:00 AM, Continue reading at the source